Lindahl advises sell-side in connection with the transfer of the Swedish biotech company CartaNA to the American Nasdaq listed company 10x Genomics. CartaNA provides a world-leading technology that allows researchers to perform in situ genome analysis and visualizations directly from tissue samples.
Lindahl's team consisted of Mattias Prage (partner in charge), Andreas Mellberg, Jens Frykstrand, Joakim Gustafsson and Therese Norenäs.
